Galmed Pharmaceuticals Sets July 10th Annual Shareholder Meeting
Ticker: GLMD · Form: 6-K · Filed: Jun 5, 2024 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing-update
Related Tickers: GLMD
TL;DR
Galmed (GLMD) holding shareholder meeting July 10th. Details in proxy filing.
AI Summary
Galmed Pharmaceuticals Ltd. announced it will hold its Annual General Meeting of Shareholders on Wednesday, July 10, 2024, at 16:00 p.m. Israel time. The meeting will take place at the offices of Meitar | Law Offices in Ramat Gan, Israel. The Notice of the Annual General Meeting and Proxy Statement are attached to the filing.
Why It Matters
This filing informs shareholders about the upcoming annual meeting where key decisions and elections will likely take place, impacting the company's governance and future direction.
Risk Assessment
Risk Level: low — This is a routine corporate announcement regarding an annual shareholder meeting, not related to significant financial or operational changes.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Registrant
- July 10, 2024 (date) — Annual General Meeting date
- Meitar | Law Offices (company) — Legal counsel and meeting venue
FAQ
When and where will Galmed Pharmaceuticals Ltd. hold its Annual General Meeting of Shareholders?
The Annual General Meeting will be held on Wednesday, July 10, 2024, at 16:00 p.m. (Israel time) at the offices of Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel.
What documents are attached to this Form 6-K filing regarding the Annual General Meeting?
A copy of the Notice of the Annual General Meeting of Shareholders and Proxy Statement and the Proxy Card are attached as Exhibit 99.1 and Exhibit 99.2, respectively.
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report that Galmed Pharmaceuticals Ltd. will hold its Annual General Meeting of Shareholders and to provide related documentation.
What is the fiscal year end for Galmed Pharmaceuticals Ltd.?
The fiscal year end for Galmed Pharmaceuticals Ltd. is December 31 (1231).
Under which SEC Act is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
Filing Stats: 276 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2024-06-05 16:16:13
Filing Documents
- form6-k.htm (6-K) — 18KB
- ex99-1.htm (EX-99.1) — 118KB
- ex99-2.htm (EX-99.2) — 29KB
- ex99-2_001.jpg (GRAPHIC) — 1KB
- 0001493152-24-022747.txt ( ) — 167KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: June 5, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer